Market Overview

ARIAD , Foundation Medicine Announce Collaboration on AP26113 Study


Medicine and ARIAD
Pharmaceuticals (NASDAQ: ARIA) today announced a genomic
profiling collaboration to study AP26113, ARIAD's investigational
dual-inhibitor of ALK and EGFR in patients with non-small cell lung
cancer (NSCLC) and other cancers. Foundation Medicine will work with
ARIAD to generate genomic profile information for patients enrolled in
ARIAD's ongoing Phase 1/2 trial and these data will be matched with
clinical observations to understand the activity and selectivity profile
of AP26113.

“It is important that we have a deep molecular understanding of
patients' tumors as they begin treatment with AP26113, especially those
patients with complex prior treatment histories,” stated Timothy P.

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (ARIA)

View Comments and Join the Discussion!

Partner Center